JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

USE OF NANOPARTICLE IN MODERN MEDICINE

[1]Pranav Kumar, [2]Vishal Shrivastava,[3]Akhilesh Kumar Singhai

School of pharmacy lnctu,
Lnctu Kolar Bhopal, India

Abstract: Nanotechnology, particularly through nanoparticles (NPs), has revolutionized modern medicine, offering new avenues for therapeutic strategies, diagnostics, and targeted drug delivery. NPs possess unique properties like size, shape, and surface charge, making them adaptable for various biomedical applications. In drug delivery, they enhance solubility and stability while reducing off-target effects. Functionalized NPs can precisely target diseased tissues, improving efficacy and minimizing side effects. Additionally, NPs are valuable in diagnostics, enabling sensitive detection of disease biomarkers through advanced imaging techniques like MRI and CT scans. In therapeutics, they play a role in gene therapy, immunotherapy, and regenerative medicine, allowing efficient gene delivery, immune modulation, and tissue regeneration. Despite their potential, challenges persist in clinical translation, including concerns about biocompatibility and scalability. Collaboration among researchers, clinicians, engineers, and regulatory agencies is crucial to optimize NP design and ensure safety. In conclusion, NPs signify a paradigm shift in medicine, promising advancements in treatment and diagnosis across a wide spectrum of diseases, ultimately improving patient outcomes and quality of life.

KEYWORDS: - NANOPARTICLE, NANOMEDICINE, CANCER, MODERN MEDICINE

1. INTRODUCTION

In recent years, the incorporation of nanotechnology into various aspects of our lives has become increasingly prevalent. This ground-breaking technology has found applications across multiple fields, marking a significant shift in how we approach innovation. With an expanding array of products and advancements featuring nanomaterials or claiming nano-based properties, it's evident that nanotechnology has permeated diverse sectors, including pharmaceutical research. Recognized within the European Union (EU) as a Key Enabling Technology, nanotechnology is now acknowledged for its potential to offer transformative medical solutions, catering to unmet healthcare needs through innovative drug development [1].

Nanotechnology encompasses the development and utilization of technologies operating at the scale of 1 to 100 nanometres [2]. Within the field of medicine, this is referred to as nanomedicine, where nanoscale structures, materials, and particles play a pivotal role in advancing healthcare [2,3]. These nanometre-sized components possess distinct physical, chemical, or biological characteristics, offering novel avenues for the creation of diagnostic and therapeutic devices and systems (see Figure 1). For instance, quantum dots represent.

fluorescent semiconductor nanoparticles whose emissions can be tailored by adjusting their size, shape, and chemical composition. They find application as probes in both in vitro and in vivo microscopy, often coated with biocompatible polymers and antibodies [4]. On the other hand, gold-based nanomaterials in rod shape can generate heat upon laser stimulation, making them a subject of clinical exploration for tumour ablation [5]. Similarly, iron oxide nanoparticles exhibit superparamagnetic properties useful in magnetic resonance imaging (MRI) and as agents in medical laboratories for capturing biological molecules in detection assays. The combination of diverse nanoparticles within a single entity paves the way for the development of nano systems capable of simultaneous therapeutic and diagnostic functions [6].

This review aims to provide a general overview of the contributions of nanoparticles to the field of medicine, rather than an exhaustive examination. It will primarily focus on technologies that have either progressed to clinical implementation or are undergoing in vivo testing. Specifically, the discussion will center around the utilization of nanoparticles in medical imaging and drug/gene delivery, highlighting examples of their applications. Additionally, readers will be directed to existing comprehensive reviews within each respective application domain wherever feasible. Finally, consideration will also be given to the environmental and societal ramifications associated with the integration of nanoparticles into contemporary medical practices.



"Fig. 1" ***Nanomaterials offer a diverse set of tuneable properties. These can be divided into physical, chemical, surface and biological properties. Physical properties include features such as size, shape, and elasticity. Chemical properties are dependent on the material used and its reactions in different environments. The surface of nanomaterials is important because it is the interface between the environment and the rest of the material. Its intrinsic properties and what it presents influence biological properties of the nanomaterial. They are measured in terms of biocompatibility, bioavailability.***

Nanomaterials are small and can be designed with a diverse range of physicochemical and biological properties on their surface and core (Fig. 1). These features make nanotechnology platforms useful for biology and medicine. The inspiration comes from intrinsic biological interactions that maintain cell function and viability, which are at the nanoscale regime. These include interactions such as intracellular trafficking, synthesis, degradation, activation or deactivation of oncogenic pathways, neurotransmitter release and receptor–ligand binding. These interactions involve binding of biomolecules through domains that are less than 10 nm in size. Biological structures such as organelles and vesicles are 100 nm or smaller in size and carry out sorting, processing, and degradation processes. The nanoparticles' small size may allow them to transport into many biological structures to disrupt molecular interactions. Researchers seek to engineer the nanomaterials to pharmacokinetics and pharmacodynamics [7].

2. APPLICATION OF NANOPARTICLE IN MEDICINE

CANCER

The utilization of nanoparticles in cancer therapy represents one of the most extensively studied areas within nanomedicine, commonly referred to as cancer nanomedicine [8]. Initially, the focus of this research was on designing nanomaterials capable of carrying either therapeutic or diagnostic agents with enhanced efficacy into tumor sites. This approach aimed to address the challenges of low accumulation at target sites and off-target effects associated with traditional small molecule chemotherapeutics and imaging agents. The development of nanomaterials stemmed from observations of gaps in the endothelial lining of tumor vessels, leading to the concept known as the Enhanced Permeation and Retention Effect, which became a fundamental principle in cancer nanomedicine. The primary objective was to engineer nanoparticles smaller than these gaps in tumor vasculature to facilitate their accumulation within tumors. However, recent research has revealed that the predominant mechanism of nanoparticle transport into the tumor microenvironment is an active process, such as transport through endothelial cells [9]. This discovery has sparked discussions and debates regarding the mechanisms underlying nanoparticle entry into solid tumors. Nonetheless, researchers continue to strive for the development of ideal cancer-targeting nanoparticles characterized by stability in vivo, minimal off-target accumulation in organs like the liver and spleen, efficient entry into tumors, and specific payload release within the tumor environment [10,11].

DRUG DELIVERY

In the short and medium term, the primary application of nanoparticle medicinal products (NMP) lies in the vectorization of active ingredients, a function exemplified by several already commercialized products such as Doxil™ and more recently Abraxane™. Typically, researchers categorize vector generations into three groups:

• First-generation vectors: nanospheres and nano capsules, which are widely recognized and readily accessible.

• Second-generation vectors: nanoparticles coated with hydrophilic polymers like polyethylene glycol (PEG), often referred to as PEGylated nanoparticles.

• Third-generation vectors, currently in the developmental phase, incorporate a biodegradable core enveloped by a polymer (such as PEG) equipped with a ligand for membrane recognition.

Presently, a significant portion of research efforts in nano delivery systems is directed towards advancing the third-generation vectors.

Traditional chemotherapy utilizes drugs that effectively kill cancer cells, but they also harm healthy cells, resulting in undesirable side effects like nausea, neuropathy, hair loss, fatigue, and compromised immune function. To address this issue, nanoparticles can serve as carriers for chemotherapeutic drugs, delivering medication directly to the tumour while minimizing damage to healthy tissue. Nanocarriers offer several advantages over conventional chemotherapy, including:

- Protection of drugs from degradation in the body before reaching their target.

- Enhanced drug absorption into tumours and cancerous cells.

- Improved control over the timing and distribution of drugs within tissues, facilitating better assessment of their efficacy by oncologists.

- Prevention of drug interactions with normal cells, thereby reducing side effects.



"Fig .2": Lapidot's® for drug delivery and molecular imaging. Credit: CEA-Leti

Passive Targeting:

Numerous nanocarrier-based drugs currently available on the market rely on passive targeting, leveraging a phenomenon termed "enhanced permeability and retention." Due to their size and surface characteristics, certain nanoparticles can penetrate blood vessel walls and accumulate in tissues. Moreover, tumors often exhibit leaky blood vessels and impaired lymphatic drainage, leading to the accumulation of nanoparticles within tumor tissues. This accumulation concentrates the attached cytotoxic drug at the site of action, protecting healthy tissue and significantly mitigating adverse side effects.

Active Targeting:

On the horizon are nanoparticles designed for active targeting, wherein drugs are specifically directed to cancerous cells based on the molecular markers present on their surface. Molecules capable of binding to specific cellular receptors can be attached to nanoparticles, enabling them to selectively target cells expressing these receptors. Active targeting strategies may even facilitate the internalization of drugs into cancerous cells by inducing cellular uptake of the nanocarrier.[12]

IMAGING AND DIAGNOSTICS:

Magnetic Resonance Imaging (MRI) Contrast Agents

A common medical application for magnetic nanoparticles is their use as contrast agents for magnetic resonance imaging (MRI). MRI is a non-invasive and high-resolution imaging modality that has become the clinical standard for visualizing anatomical structures. Despite its wide clinical use, MRI has low signal intensity and sensitivity, which makes rapid and accurate diagnoses difficult [13]. Consequently, approximately 40–50% of MRI procedures require contrast agents for image enhancement [14]. Gadolinium chelates (GCs) are the current clinical standard for MRI because of their low toxicity, short circulation half-life, and positive contrast enhancement [15,16,21]. However, concerns have been raised regarding potential toxicity, non-specific biodistribution, poor cellular uptake and retention, and the sub-optimal contrast enhancement of GCs [17,18,21]. As a result,

many improvements and alternatives to GCs have been developed [19,20,21]



"Fig. 3": T1-weighed MRA of a mouse at (A) 4, (B) 12, and (C) 20 min post injection with ZES-SPIONs. MRA of (D) canine (beagle) and (E) non-human primate (macaque) animal models post PEG-IONC injection. Dynamic susceptibility contrast perfusion-weighted images of left cerebral ischemia in a macaque (F) before and (G) after bolus injection of PEG-IONC. (A–C) Reproduced with permission from Wei et al., Proceedings of the National Academy of Sciences of the United States of America; published by National Academy of Science, 2017. (D–G) Reproduced with permission from Lu Y. et al., Nature Biomedical Engineering; published by Springer Nature, 2017.

Over the past 25 years, medical imaging has transitioned from a peripheral role in healthcare to a vital diagnostic tool. Molecular imaging and image-guided therapy have become fundamental for disease monitoring and the advancement of various in-vivo nanomedicine applications. Initially, imaging techniques could only identify tissue changes in advanced disease stages. However, the introduction of contrast agents facilitated easier disease localization and mapping. Today, through the integration of nanotechnology, imaging tools and contrast agents are undergoing significant refinement, aiming to detect diseases at their earliest stages, potentially even at the single-cell level, and to monitor therapy effectiveness more accurately.

Targeted molecular imaging plays a crucial role in diverse diagnostic applications, including identifying inflammation sites, localizing and staging tumors, visualizing vascular structures, and examining specific disease states and anatomical structures. It also contributes to research on controlled drug release, evaluating drug distributions, and early detection of unexpected and potentially hazardous drug accumulations. The convergence of nanotechnology and medical imaging promises a forthcoming revolution in molecular imaging, often referred to as nano-imaging, enabling the detection of single molecules or cells within complex biological environments.

"Fig .4": Diffusion Magnetic Resonance Imaging of human brain. Credit: CEA

Vaccine

In the last few decades, nanotechnology was applied on a variety of scientific fields, including medicine, which gave rise to the birth of a new scientific discipline called nanomedicine [22]. This relatively recent field became a multidisciplinary scientific area with many researchers involved, such as engineers, physicists, chemists, biologists, physicians, and even legislators [23]. One of the benefits of nanomedicine is its nanometric scale, which is the scale of many biological mechanisms in the human body [24]. This fact allows many nanoplatforms to cross some natural barriers and, therefore, access new sites of delivery and/or interact with DNA or proteins at different levels, in different organs, tissues, or cells. Nanomedicine is expected to be a very important instrument for personalized, targeted, and regenerative medicine thanks to the development of new treatments that could be breakthroughs in healthcare [25].

Gene Therapy

Nanoparticles are used to deliver genetic material such as DNA or RNA to target cells for gene therapy applications. They protect the fragile genetic material from degradation and facilitate its uptake by cells, offering potential treatments for genetic disorders, cancers, and infectious diseases.

Regenerative Medicine

Nanoparticles are employed in tissue engineering and regenerative medicine to deliver growth factors, cytokines, or stem cells to damaged tissues, promoting tissue repair and regeneration. They can also act as scaffolds for cell attachment and proliferation, facilitating the construction of functional tissue substitutes.

Antimicrobial Applications

Nanoparticles exhibit antimicrobial properties against a wide range of pathogens, including bacteria, viruses, and fungi. They can be incorporated into medical devices, coatings, or wound dressings to prevent infections and enhance wound healing.

These applications highlight the versatility and potential of nanoparticles in advancing modern medicine, offering solutions for various diseases and healthcare challenges. However, ongoing research is needed to address safety concerns, optimize nanoparticle design, and translate these innovations into clinical practice.[23]

3. TYPE OF NANO PARTICLE USED IN MEDICINE



"Fig.5": Generalized diagram of the types of nanoparticles and their main biomedical applications. Based on their chemical composition, nanoparticles can be divided into three main groups: organic, inorganic, and carbon-based. Each category includes several types of Nano formulation.

Regarding their chemical compounds, nanoparticles (NPs) can be divided into three main groups: organic nanoparticles (such as liposomes and polymers), inorganic nanoparticles (including metals, metal oxides, ceramics, and quantum dots), and carbon-based nanoparticles. In general, NPs retain the chemical properties of their bulk materials, which can be advantageous when selecting a specific NP for a biomedical application. The NPs utilized in nanomedicine encompass a variety of types.

Liposome Nanoparticles:

Liposomes are spherical vesicles composed of a lipid bilayer enclosing an aqueous core. The amphiphilic molecules used to form these vesicles mimic biological membranes, enhancing the efficacy and safety of various drugs. Liposomes find extensive use in delivering chemotherapeutic agents for cancer treatment.[26] They have the capability to encapsulate a wide range of bioactive substances, including pharmaceutical drugs and food ingredients. Due to their high biocompatibility and biodegradability, liposomes hold significant potential in nanomedicine, as well as in the food and cosmetics industries.[27] Recent advancements in nanoliposome technology have provided opportunities for food technologists, enabling controlled release and encapsulation of food ingredients, and enhancing the stability and bioavailability of sensitive compounds. Liposomes serve as an advanced technology for delivering active molecules to specific targets.[26]

Polymeric Nanoparticles:

Polymeric nanoparticles are renowned for their biodegradability and biocompatibility, making them the most employed nanoparticles in drug delivery systems. They can be derived from natural polymers like chitosan or synthetic polymers such as polylactides (PLA), poly (methyl methacrylate) (PMMA), or polyethylene glycol (PEG). These nanoparticles offer excellent potential for surface modification and possess favorable pharmacokinetic profiles, as their size and solubility can be precisely controlled during fabrication. Various methods can be employed for preparing polymeric nanoparticles, including two-step procedures like emulsification-solvent evaporation, emulsification-solvent diffusion, and emulsification–reverse salting-out, as well as one-step procedures such as nanoprecipitation methods, dialysis, and supercritical fluid technology [28].

Metallic Nanoparticles:

Metallic nanoparticles encompass precious metals like gold or silver, as well as magnetic metals such as iron oxide, cobalt, and manganese-doped ferrites. Gold nanoparticles (AuNPs), for instance, exhibit distinctive electronic and optical properties. They are known for their biocompatibility, non-toxicity, and the ability to modify their surface with other biomolecules owing to their negative charge [29,30].

Metal Oxide Nanoparticles:

Metal oxide nanoparticles demonstrate catalytic and antioxidant properties, along with chemical stability, optical characteristics, and biocompatibility, rendering them suitable for numerous biomedical applications. Among the most utilized are iron oxide (Fe_3O_4), titania (TiO_2), zirconia (ZrO_2), and more recently, ceria (CeO_2) [31].

Ceramic Nanoparticles:

Ceramic nanoparticles represent inorganic compounds possessing porous characteristics, which have recently emerged as carriers for drugs. They exhibit the capability to transport molecules such as proteins, enzymes, or drugs without undergoing swelling or compromising their porosity due to external factors such as pH or temperature variations [32].

Quantum Dots:

Quantum dots (QDs) are nanoparticles composed of semiconductor materials exhibiting fluorescent properties. Typically, QDs comprise a semiconductor core, such as cadmium–selenium (CdSe), cadmium–tellurium (CdTe), indium–phosphate (InP), or indium–arsenate (InAs), which is encapsulated with a shell material like zinc sulfide (ZnS). This shell serves to enhance their optical and physical characteristics and to mitigate the release of toxic heavy metals [33].

Carbon-Based Nanoparticles:

Carbon-based nanoparticles encompass fullerenes and nanotubes. Fullerenes represent novel carbon allotropes characterized by a polygonal structure composed exclusively of 60 carbon atoms. Carbon nanotubes, on the other hand, are typically synthesized via chemical vapor deposition of graphite. Two primary classes of carbon nanotubes exist: single-walled (SWCNT) and multiwalled (MWCNT). The latter demonstrates potent antimicrobial properties [34].

4. NANO MEDICINE THERAPEUTICS

Nanomaterials are typically used as delivery vehicles to transport drugs to the targeted diseased site. In many diseases, there are candidate drugs that perform with high efficacy in vitro. However, in vivo performance is hampered by poor pharmacokinetics and pharmacodynamics [35,36]. Small molecule drugs, proteins and nucleic acid face several challenges once injected into the body. They adsorb serum proteins that mark them for immune recognition and subsequent processing. Drugs below the renal filtration cut-off (<6.5 nm) are excreted, endonucleases degrade nucleic acid drugs, and the innate immune system recognizes them as foreign material [35,37]. These drugs also undergo extensive first-pass metabolism in the liver. Here, the liver enzymes metabolize drugs and reduce the number of active drug molecules at the target site. Non diseased organs such as the liver, spleen, skin and other tissues can sequester the drug and reduce their final accumulation at the target organs. Recognition by off-target cells at these sites can yield serious side effects and organ damage that limit their use clinically [38]. Whilst many drug candidates exist, how they are recognized and processed by the body leads to low accumulation at the targeted site and side effects, leading to a translational barrier to these drugs.

5. CHALLENGES AND OUTCOME

The pace of clinical translation of nanomedicine has gained momentum recently. One of the most successful ventures has been Alnylam Pharmaceuticals, which have used the LNP platform along with nucleic acid modifications to develop Onpattro as described above. Other recent success include Vyxeous and COVID-19 vaccines from Pfizer-BioNTech and Moderna. However, many other companies failed clinical trials or are still searching for the optimal design for their clinical applications [39,40]. These failures have instilled an urgent need to understand why formulations, trials and companies failed. This has amplified research effort in the last decade towards understanding nanoparticle– biological (nano-bio) interactions. Whilst there were many optimization studies performed in the 1990s to design liposomes drug delivery applications, many researchers consider the 2000s as the start of nano-bio interactions research . These studies focused on how nanoparticle design (e.g. size, shape, surface chemistry, stiffness) systematically impact therapeutic effectiveness, immune response, delivery, toxicity and other biological functions. The findings from these systematic studies have laid a foundation of general principles and stimulated mechanistic studies between nanoparticles and different biological environments. Nano bio interaction research aims to probe the nanoparticle interface with biology to link nanoparticle design to medical performance (e.g. therapeutic response, imaging signal). Nano-bio interactions are now a ‘fundamental’ research arm in the field of nanomedicine [41,42].



Commercial and Practical Feasibility:

The initial hurdle in the development of any nanomedicine revolves around its commercial and practical viability concerning its primary target indication. This entails assessing both the potential for enhanced patient benefits and the size of the prospective patient population.

Clinical Development Feasibility:

Demonstrating improved efficacy or safety, as defined earlier, presents significant challenges that necessitate extensive and costly clinical trials. This leads to the second challenge: clinical development feasibility. Designing proper clinical studies is crucial to ensure that a new nanomedicine product can ultimately demonstrate substantial clinical potential in pivotal trials. Selecting appropriate endpoints that accurately reflect the anticipated enhanced patient benefits, and that are acceptable to both government bodies and insurers, is essential.

Preclinical Efficacy to Clinical Outcome:

The third challenge involves translating preclinical efficacy into clinical outcomes. For nanomedicines, complexities arise concerning response rate variability and predicting therapeutic efficacy in patients, especially for molecularly targeted therapies. It is crucial to exercise caution in placing too much emphasis on positive preclinical study results, as there are numerous instances where drugs fail to meet expectations in patients despite promising results in animal studies, particularly evident in oncology.[43]

Preclinical Toxicology to Patient Safety:

The fourth challenge pertains to bridging the gap between preclinical toxicology studies and ensuring safety in patients. Nanomedicines may present safety concerns at multiple levels beyond the intrinsic toxicity of the active pharmaceutical ingredient (API) itself.

Firstly, when delivered via nanoparticles, the biodistribution of drug molecules often undergoes significant changes, potentially resulting in local overexposure in certain organs. Nanoparticles have a known tendency to accumulate in lymphoid organs, and some polymer-bound drugs may preferentially accumulate in the kidneys.

Secondly, unexpected toxicity related to nanomedicines can arise from excipients that have not been adequately proven safe in humans. To mitigate potential safety issues at these levels, it is advisable to conduct early preclinical pharmacokinetic and biodistribution studies. These studies should assess organ drug exposure and toxicity through extensive histopathology and established clinical chemistry protocols, with drug-free nanocarriers serving as key controls.

The third level at which nanomedicine-related safety issues may arise pertains to immunological responses, which are challenging to predict based on studies in small laboratory animals. These responses, such as hypersensitivity reactions, occur in a relatively small percentage of humans upon nanomedicine administration but can be severe and occasionally life-threatening. The activation of the complement cascade and specific nanoparticle-blood cell interactions contribute to immunological side effects. Addressing these issues involves employing in vitro complement binding and cell interaction assays, as well as conducting preclinical safety studies in larger animals, notably pigs.[44]

Chemistry, Manufacturing, and Control (CMC):

The fifth and final challenge to address involves effectively managing the chemistry, manufacturing, and quality control (CMC) aspects of nano medicinal drugs. Unlike conventional drug products, the in vivo performance of nanomedicines, including biodistribution, target accumulation, and drug availability at pathological and non-pathological sites—upon which their efficacy and safety critically depend—is directly influenced by the physicochemical properties of the nanoparticle carrying the drug.[45]

While stringent quality control is essential for all medicinal products, nanomedicine presents additional challenges. Critical quality attributes such as particle size, surface morphology, drug loading, and release necessitate a range of specialized quality control assays beyond standard checks. Early consideration of critical quality attributes during formulation design, with defined narrow specifications for optimal performance, is paramount.

Manufacturing processes must be robust, scalable, and adhere strictly to good manufacturing practice (GMP) guidelines. Preferably, manufacturing should also adhere to quality-by-design (QbD) principles, incorporating in-process controls to monitor key quality attributes during compounding. This enables adjustments to critical process parameters, such as temperature and pressure, to ensure the final formulation meets set specifications safely.

Assessing composition, excipients, and key quality attributes early in nanomedicine design, preferably even before preclinical testing in animal models, is crucial. Although scalable manufacturing methods are typically developed later, awareness of potential issues such as sterility and manufacturing-related impurities early in the process can help avoid costly reformulations that may require revisiting the entire preclinical data package.

Therefore, careful consideration of chemistry, manufacturing, and control aspects as early as possible in nanomedicine development significantly contributes to translational success.[45]

6. CURRENT RESERCH AND DEVELOPMENT:

As of NOW last update in January 2022, research and development on nanoparticles in modern medicine are ongoing and continually evolving. Some recent trends and areas of focus include:

1. Targeted Drug Delivery: Researchers are exploring advanced nanoparticle-based drug delivery systems to target specific cells or tissues more effectively, reducing side effects and improving therapeutic outcomes. This includes the development of smart nanoparticles that can respond to physiological cues or stimuli to release drugs at precise locations.

2. Theragnostic: There is a growing interest in theragnostic nanoparticles, which combine therapeutic and diagnostic capabilities in a single platform. These nanoparticles allow simultaneous imaging of disease and targeted delivery of therapeutic agents, enabling personalized medicine approaches.

3. Immunotherapy: Nanoparticles are being investigated as vehicles for delivering immunotherapeutic agents, such as checkpoint inhibitors or vaccines, to modulate the immune response against cancer or infectious diseases. They can enhance the efficacy of immunotherapy while minimizing systemic toxicity.

4. Gene Editing: Nanoparticles are being explored as carriers for gene editing tools, such as CRISPR-Cas9, to precisely modify genetic material within cells. This approach holds promise for treating genetic disorders and advancing personalized medicine.

5. Bioimaging: Nanoparticles with unique optical, magnetic, or radioactive properties are being developed for advanced bioimaging techniques, allowing for high-resolution visualization of biological structures and processes. These nanoparticles enable early disease detection, monitoring of treatment responses, and image-guided interventions.

6. Regenerative Medicine: Nanoparticles are being investigated for their potential in promoting tissue regeneration and repair. They can deliver growth factors, stem cells, or scaffolds to damaged tissues, facilitating tissue engineering and regenerative therapies.

7.Combination Therapy: Researchers are exploring the synergistic effects of combining different therapeutic modalities, such as chemotherapy with photothermal therapy or immunotherapy with targeted drug delivery, using multifunctional nanoparticles. This approach aims to overcome treatment resistance and improve overall therapeutic outcomes.

8.Biosensing and Diagnostics: Nanoparticles are being utilized for the development of sensitive and selective biosensors for detecting biomarkers associated with various diseases. These nanoparticles enable rapid and accurate diagnosis, leading to early intervention and improved patient outcomes.

Overall, research and development efforts in nanoparticle-based technologies continue to advance the field of modern medicine, offering innovative solutions for diagnosis, treatment, and monitoring of diseases. These advancements hold the potential to revolutionize healthcare by providing more precise and effective therapeutic strategies.

ETHICAL AND SOCIAL IMPLICATIONS:

Ethical Implications:

When nanotechnology is utilized to develop commercial products, it necessitates a systematic approach that considers ethical aspects from inception through to discontinuation. Ethical concerns arise due to the potential benefits and risks associated with nanotechnology. A universal definition and understanding of nanotechnology worldwide would aid in regulating the technology more effectively. Some of the ethical issues related to the advancement of nanotechnology include:

1.Risk Assessment: Current methods for assessing the risks associated with nanotechnology are insufficient. The reduction in size of materials to the nanoscale alters their properties, such as increased surface area and toxicity. Adequate risk assessment protocols need to be established [46].

2.Equitable Distribution: There are concerns about the unequal distribution of nanotechnology, which may privilege wealthy individuals or nations. Access to nanotechnology should be equitable across developed and developing nations, urban and rural areas, and socioeconomic classes [47].

3.Unintended Consequences: Nanotechnology may have unintended consequences that arise from its use in various sectors. For example, while nanotechnology in medicine may improve the health and longevity of elderly individuals, unintended consequences may include population growth, extended retirement, and increased government spending on pensions [48].

4.Security Issues: Nanotechnology raises security concerns related to the storage and potential misuse of personal data. There is a risk that personal data collected through nanotechnology could be exploited by various sectors, such as insurance companies and consumer manufacturing companies, leading to privacy breaches and targeted advertising.

5.Freedom of Choice: Balancing consumer freedom of choice with the need to protect the environment and public health poses ethical dilemmas. Consumers should have the right to choose products, but measures must be in place to prevent adverse environmental and health impacts [49].

6. Animal Testing: Ethical debates surround the use of animal testing during clinical trials of nanotechnology-based products. While some argue it is necessary to ensure product safety for humans, others raise concerns about the ethics of using animals for experimentation.

7.Toxicity: Nanomaterials may pose toxicity risks due to their nanoscale size and potential accumulation in the environment or human body. More research is needed to understand the properties of nanomaterials and their potential health impacts.

8.Patenting Issues: Challenges exist in patenting nanotechnology-related discoveries due to differences in patent laws between countries and the evolving nature of nanoscience. Clear guidelines are needed to address patenting issues and ensure fair competition and innovation.

9.Misinformation: False information about nanotechnology may lead to public skepticism and hinder research and commercialization efforts. Transparent reporting and dissemination of accurate information are essential to address misconceptions and foster trust in nanotechnology.

Addressing ethical issues related to nanotechnology requires consideration of principles such as fairness, justice, power, and equity. Research ethics should guide transparent and detailed research practices to ensure ethical conduct in nanotechnology development and implementation.

Societal Implications:

Advancements in medical applications using nanotechnology have enabled improvements in physical strength, memory enhancement, and the treatment of disabilities such as Parkinson's disease. The ability to design systems at the atomic scale offers the potential to reshape the structure of materials in our surroundings. However, these advancements also raise several societal implications:[50]

1.Conflict of Interest: Conflicting interests among various stakeholders can hinder the growth of nanotechnology. Misalignment between research intentions and application needs can complicate decision-making processes[49]

2.Technology Replacement and Workforce Issues: The transition from older to newer technologies, such as with nanotechnology, may disrupt existing industries and require workforce reskilling. Additionally, ensuring workforce safety while working with new technologies is crucial.

3.Convenience and Demand: Once new technologies become technically and commercially feasible, they become convenient for users and innovators. The demand for nanotechnology is driven by its potential benefits and applications.

4.Environmental Pollution: Nanoparticles' size and properties can affect the environment, particularly during manufacturing and disposal processes. The environmental impact of nanotechnology, such as the release of pollutants during battery manufacturing, needs to be carefully considered.

5.Socioeconomic Disparities: Nanotechnology penetration follows a pattern similar to the adoption of other technologies, starting from wealthy nations to poorer ones. This can exacerbate socioeconomic disparities unless efforts are made to ensure equitable access [51]

6.Accidental Spread: Similar to biotechnology, accidental spread of nanotechnology may lead to unforeseen health and environmental consequences. Lessons from past experiences can inform strategies for handling and engaging with nanotechnology responsibly.

7.Security Risks: The small size and enhanced properties of nanoparticles could potentially be misused as terrorist weapons. Efforts to mitigate such risks should include researching and developing countermeasures alongside technological advancements.

8.University-Industry Collaboration: Collaborations between universities and industries should not only focus on technology development but also consider ethical implications. They should educate students and society about the ethical aspects of nanotechnology and contribute to balanced national growth and global leadership.

Future Perspectives:

Nanomedicine represents one of the most captivating areas of research today, with significant progress made over the last two decades. The field has seen the filing of thousands of patents and the completion of numerous clinical trials, particularly in the realm of cancer diagnosis and therapy. Nanoparticles offer the potential to deliver precise amounts of drugs to targeted cells, such as cancer cells, while sparing normal cells, paving the way for continued research and development in nanomedicine and nano-drug delivery systems for years to come.However, there are areas for improvement and further research. The nanoparticles mentioned in this communication vary in size, with some measuring in nanometers and others in sub-micrometers. Future research should focus on materials with more consistent uniformity and enhanced drug loading and release capacities. Metals-based nanoparticles, such as gold and silver, hold promise for both diagnostic and therapeutic applications, potentially expanding the reach of nanomedicine in the future. For example, gold nanoparticles have shown promising results in enhancing the susceptibility of soft tumor tissues to heat therapy based on radiation.Despite the promising future prospects of nanomedicine and nano-drug delivery systems, their impact on healthcare remains limited. This is partly due to the novelty of the field, with only two decades of dedicated research, and many fundamental attributes still unknown. Future research should focus on identifying key biological markers of diseased tissues to enable precise targeting without disrupting normal cellular processes. Understanding disease at the molecular level and identifying molecular signatures will be crucial for advancing nanomedicine applications. In addition to known nanoprobes and nano theragnostic products, further research will be essential for the broader application of nanomedicine. As our understanding of diseases improves and new diagnostic and therapeutic avenues emerge, nanomedicine is poised to play an increasingly significant role in healthcare. Continued research and innovation will be key to unlocking the full potential of nanomedicine and realizing its benefits across a wide range of medical applications.

REFERENCES: -

1. Bleeker et al., 2013; Ossa, 2014; Tinkle et al., 2014; Pita et al., 2016).
2. Kim BYS, Rutka JT, Chan WCW. Nanomedicine. N Engl J Med. 2010;363:2434–43.
3. Nel AE, Madler L, Velegol D, Xia T, Hoek EMV, Somasundaran€ P, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8:543–57.
4. Kairdolf BA, Smith AM, Stokes TH, Wang MD, Young AN, Nie S. Semiconductor quantum dots for bioimaging and biodiagnostic applications. Annu Rev Anal Chem.
5. 2013;6:143–62.
6. Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev. 2012;41:2256–82.
7. Vallabani NVS, Singh S. Recent advances and future prospects of iron oxide nanoparticles in biomedicine and diagnostics. 3 Biotech. 2018;8:279.
8. Zhu M, Nie G, Meng H, Xia T, Nel A, Zhao Y. Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Acc Chem Res. 2013;46:622–31.
9. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20–37.
10. Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19:566–75.
11. Youn YS, Bae YH. Perspectives on the past, present, and future of cancer nanomedicine. Adv Drug Deliv Rev. 2018;130:3–11.
12. van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14:1007–17.
13. Debiotech: DebioSTARTM implantable drug delivery technology for the sustained delivery of pharmaceutical compounds.(http://www.debiotech.com/products/drugdd/debiostar.htmlUH)UH
14.
15. Smith, B.R.; Gambhir, S.S. Nanomaterials for In Vivo Imaging. Chem. Rev. 2017, 117, 901–986. [CrossRef]
16. Shen, Z.; Wu, A.; Chen, X. Iron Oxide Nanoparticle Based Contrast Agents for Magnetic Resonance Imaging. Mol. Pharm. 2017, 14, 1352–1364. [CrossRef] [PubMed]
17. Daldrup-Link, H.E. Ten Things You Might Not Know about Iron Oxide Nanoparticles. Radiology 2017, 284, 616–629. [CrossRef]
18. Shen, S.; Ding, W.; Ahmed, S.; Hu, R.; Opalacz, A.; Roth, S.; You, Z.; Wotjkiewicz, G.R.; Lim, G.; Chen, L.; et al. Ultrasmall Superparamagnetic Iron Oxide Imaging Identifies Tissue and Nerve Inflammation in Pain Conditions. Pain Med. 2018, 19, 686–692. [CrossRef] [PubMed]

19. Choi, J.W.; Moon, W.-J. Gadolinium Deposition in the Brain: Current Updates. Korean J. Radiol. 2019, 20, 134–147. [CrossRef] [PubMed]
20. Pasquini, L.; Napolitano, A.; Visconti, E.; Longo, D.; Romano, A.; Tomà, P.; Espagnet, M.C.R. Gadolinium-Based Contrast Agent-Related Toxicities. CNS Drugs 2018, 32, 229–240. [CrossRef] [PubMed]
21. Fortin, M.-A. Magnetic Nanoparticles Used as Contrast Agents in MRI: Relaxometric Characterisation. In Magnetic Characterization Techniques for Nanomaterials; Kumar, C.S.S.R., Ed.; Springer: Berlin, Germany, 2017; pp. 511–555.
22. Stinnett, G.; Taheri, N.; Villanova, J.; Bohloul, A.; Guo, X.; Esposito, E.P.; Xiao, Z.; Stueber, D.; Avendano, C.; Decuzzi, P.; et al. 2D Gadolinium Oxide Nanoplates as T 1 Magnetic Resonance Imaging Contrast Agents. Adv. Heal. Mater. 2021, 10, 2001780.
23. [CrossRef]
24. Wahsner, J.; Gale, E.M.; Rodríguez-Rodríguez, A.; Caravan, P. Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. Chem. Rev. 2019, 119, 957–1057. [CrossRef] [PubMed]
25. Kim, B.Y.S.; Rutka, J.T.; Chan, W.C.W. Nanomedicine. N. Engl. J. Med. 2010, 363, 2434–2443. [Google Scholar] [CrossRef] [Green Version]
26. Webster, T.J. Nanomedicine: What's in a Definition? Int. J. Nanomed. 2006, 1, 115–116. [Google Scholar] [CrossRef] [PubMed]
27. Pelaz, B.; Alexiou, C.; Alvarez-Puebla, R.A.; Alves, F.; Andrews, A.M.; Ashraf, S.; Balogh, L.P.; Ballerini, L.; Bestetti, A.; Brendel, C.; et al. Diverse Applications of Nanomedicine. ACS Nano 2017, 11, 2313–2381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
28. Lammers, T.; Ferrari, M. The Success of Nanomedicine. Nano Today 2020, 31, 100853. [Google Scholar] [CrossRef]
29. Y. Panahi, M. Farshbaf, M. Mohammadhosseini et al., "Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications," Artificial Cells, Nanomedicine, and Biotechnology, vol. 45, no. 4, pp. 788–799, 2017.
30. Y. Malam, M. Loizidou, and A. M. Seifalian, "Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer," Trends in Pharmacological Sciences, vol. 30, no. 11, pp. 592–599, 2009.
31. K. M. El-Say and H. S. El-Sawy, "Polymeric nanoparticles: promising platform for drug delivery," International Journal of Pharmaceutics, vol. 528, no. 1-2, pp. 675–691, 2017.
32. C. R. Patra, R. Bhattacharya, D. Mukhopadhyay, and
33. P. Mukherjee, "Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer," Advanced Drug Delivery Reviews, vol. 62, no. 3, pp. 346–361, 2010.
34. P. C. Chen, S. C. Mwakwari, and A. K. Oyelere, "Gold nanoparticles: from nanomedicine to nanosensing," Nanotechnology, Science and Applications, vol. Volume 1, pp. 45–66, 2008.
35. S. Andreescu, M. Ornatska, J. S. Erlichman, A. Estevez, and J. C. Leiter, "Biomedical applications of metal oxide nanoparticles," in Fine Particles in Medicine and Pharmacy, pp. 57– 100, Springer, Boston, MA, 2012.
36. D. Singh, P. Dubey, M. Pradhan, and M. R. Singh, "Ceramic nanocarriers: versatile nanosystem for protein and peptide delivery," Expert Opinion on Drug Delivery, vol. 10, no. 2, pp. 241–259, 2013.
37. S. Ghaderi, B. Ramesh, and A. M. Seifalian, "Fluorescence nanoparticles 'quantum dots' as drug delivery system and their toxicity: a review," Journal of Drug Targeting, vol. 19, no. 7, pp. 475–486, 2011.
38. S. Maleki Dizaj, A. Mennati, S. Jafari, K. Khezri, and K. Adibkia, "Antimicrobial activity of carbon-based nanoparticles," Advanced Pharmaceutical Bulletin, vol. 5, no. 1, pp. 19–23, 2015.
39. Nichols JW, Bae YH. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today. 2012;7:606–18.
40. Metselaar JM, Lammers T. Challenges in nanomedicine clinical translation. Drug Deliv Transl Res. 2020;10:721–5.
41. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165–70.
42. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216. 27 Land WG. Innate immune recognition molecules. Damage Ass Mol Patt Hum Dis. 2018;43–108.
43. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014;34:106–35.
44. He H, Liu L, Morin EE, Liu M, Schwendeman A. Survey of clinical translation of cancer nanomedicines—Lessons learned from successes and failures. Acc Chem Res. 2019;52:2445–61.
45. Ledford H. Bankruptcy filing worries developers of nanoparticle cancer drugs. Nature. 2016;533:304–5.
46. Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, et al. Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol. 2018;4: 1344–51.
47. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108: 25–38.
48. Szebeni J, Simberg D, González-Fernández Á, Barenholz Y, Dobrovolskaia MA. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol. 2018;13(12): 1100–8.
49. Ragelle H, Danhier F, Préat V, Langer R, Anderson DG.

50. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin Drug Deliv. 2017;14:851–64.
51. Baran, Agnieszka.: Nanotechnology: legal and ethical issues. Engineering Management in Production and Services 8, no. 1: pp. 47-54. (2016).
52. Marková, Bibiána.: The main ethical issues with nanotechnology in the future context." Zeszyty Naukowe. Organizacja i Zarządzanie/Politechnika Śląska (2015).
53. Gebeshuber, Ilse C.: Social, health and ethical implications of nanotechnology. na, (2007).
54. Lewenstein, Bruce V.: What counts as a „social and ethical issue" in nanotechnology? In Nanotechnology challenges: Implications for philosophy, ethics and society, pp. 201-216. (2006).
55. Khan, Ahmed S., and Aram Agajanian.: Incorporating Social and Ethical Implications of Nanotechnology in the Engineering and Technology Curricula. In American Society for Engineering Education. American Society for Engineering Education, (2011).
56. Wolfson, Joel Rothstein.: Social and ethical issues in nanotechnology: lessons from biotechnology and other high technologies Biotechnology Law Report 22, no. 4: pp. 376-396. (2003).